麻豆成人免费视频_东京热无码AV在线_四虎成人www成人影视网址_亚洲国产成人A精品不卡在线_欧韩av_中文精品一卡2卡3卡4卡

Zishan Pharmaceutical, a subsidiary of Hongdou Group, has taken a significant step in its development within the capital market by being publicly listed on the New Third Board. As a national high-tech enterprise and a specialized "Little Giant" company in Jiangsu Province, Zishan Pharmaceutical maintains a leading position in the domestic market for paclitaxel-based drugs.

Established in 2004, Zishan Pharmaceutical is a pharmaceutical company operating in the field of Hongdou’s health industry. The company primarily focuses on the research, development, production, and sale of paclitaxel-based anti-tumor raw materials, formulations, and traditional Chinese medicine decoctions. It adheres to a business layout of "raw materials + formulations + CMO," forming a vertically integrated industrial chain encompassing raw material extraction, synthesis, formulation production, and sales, thus maintaining a leading position in the domestic paclitaxel-based drug market.

Zishan Pharmaceutical has always upheld the quality philosophy of "meticulous pharmaceutical manufacturing, precise management, and rigorous control." It has established a high-standard GMP quality specification system, with multiple raw material products leading in terms of quality and technology. Its paclitaxel injection, through generic drug quality and efficacy consistency evaluation, has been selected in the fifth batch of national drug procurement, satisfying customer needs with high-quality product standards. As of the end of October this year, Zishan Pharmaceutical has shipped over a million units of paclitaxel injection.

The company possesses a national-level postdoctoral workstation, and its anti-cancer drug paclitaxel was included in the National Torch Program in 2006. Zishan Pharmaceutical has developed a rich pipeline of anti-tumor drugs, completing the full industry chain integration from raw materials to formulations. Currently, it has 13 ongoing research projects, including 8 raw material projects and 5 formulation projects, primarily focused on paclitaxel-based drugs while continuously expanding into new clinically significant varieties. The company has increased its research and development investment in recent years, with annual R&D investment accounting for over 10%. As of December 2022, the company has been granted 54 invention patents and 1 utility model.

To accelerate its high-end and intelligent development, Zishan Pharmaceutical initiated the Intelligent Factory Project for high-end and complex anti-tumor formulations in October 2021. The first phase of the project involves an investment of 323 million yuan, with an annual production capacity of 20 million bottles of anti-tumor injections and 100 million tablets of anti-tumor solid preparations after being put into operation. This will generate an output value of over 1.5 billion yuan and an annual profit of 300 million yuan. The project will establish three anti-tumor formulation production lines, all of which will comply with top international standards such as China's GMP, the U.S. FDA, and the EU. The project will employ state-of-the-art intelligent equipment and facilities, with computerized systems covering the entire isolation filling line, aseptic transportation, and lyophilization, ensuring full automation and intelligence throughout the production process. The project is currently under intensive construction and is expected to be completed by October 2023, significantly enhancing the company's formulation capacity, production technology level, and product market competitiveness.